Send to

Choose Destination
Low Urin Tract Symptoms. 2011 Apr;3(1):43-50. doi: 10.1111/j.1757-5672.2011.00091.x.

Efficacy, Safety and Tolerability of Fesoterodine in Asian Patients with Overactive Bladder.

Author information

Department of Urology, Fukushima Medical University School of Medicine, Fukushima, JapanDepartment of Urology, Shinshu University School of Medicine, Nagano, JapanDepartment of Urology, Yamanashi University, Yamanashi, JapanDepartment of Medical Informatics, Japan Labor Health and Welfare Organization, Kumamoto Rosai Hospital, Kumamoto, JapanDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaDepartment of Urology, College of Medicine, Korea University, Seoul, KoreaDepartment of Surgery, Taipei Veterans General Hospital and National Yang Ming University, Taipei, TaiwanDepartment of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, TaiwanDepartment of Surgery, Kwong Wah Hospital, Hong Kong, ChinaPfizer Japan Inc, Tokyo, Japan.



To assess the efficacy, safety, and tolerability of fesoterodine 4 and 8 mg once daily (QD) compared with placebo in Asian subjects with overactive bladder (OAB) after 12 weeks of treatment.


This phase II, dose-finding study consisted of a 2-week placebo run-in period followed by a 12-week, randomized, double-blind, placebo-controlled, treatment period. Eligible subjects were aged ≥20 years with ≥8 micturitions per 24 h and ≥1 urgency urinary incontinence (UUI) episodes per 24 h reported in a 3-day diary. The subjects were randomized to receive placebo, fesoterodine 4 mg, or fesoterodine 8 mg QD for 12 weeks.


Of 1232 subjects who entered the placebo run-in period, 951 received double-blind treatment. The mean number of UUI episodes per 24 h at baseline was 2.2 among the three treatment groups. The two fesoterodine groups showed statistically significant decreases from baseline in the mean number of UUI episodes per 24 h at week 12 (primary endpoint) compared with placebo. Most all-causality adverse events (e.g. dry mouth and constipation) were mild or moderate. The percentage of subjects with severe adverse events was low and similar among the treatment groups (placebo, 1.3%; fesoterodine 4 mg, 1.9%; fesoterodine 8 mg, 1.0%).


Fesoterodine 4 and 8 mg QD were significantly better than placebo in improving OAB symptoms. Overall, the two fesoterodine dosing regimens were well tolerated. These results suggest that fesoterodine 4 and 8 mg QD are effective and well-tolerated treatments for OAB in Asian subjects.


fesoterodine; overactive bladder; randomized controlled trial

Supplemental Content

Loading ...
Support Center